
November 16, 2021
ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep
Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.
Founded in 2012
Over $2 billion of capital
Preferred partners for entrepeneurs, world-class scientists and strategic partners
ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep
Vertex signs another Mammoth-sized CRISPR deal with $650M in Biobucks on the Line
Google Provider of At-home Covid-19 tests is Now a $3 Billion Company Traded on Nasdaq
Exclusive: Decheng's Inside View of Merck's $2.75 Billion Acquisition of VelosBio
Exclusive: The Story Behind How Cirina, a $12 Million Hong Kong Diagnostics Startup, Became Part of Illumina